Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy
This study is evaluating whether acupuncture may help reduce hot flashes in men receiving hormone therapy for prostate cancer. Hot flashes are a common side effect of androgen deprivation therapy (ADT) and may negatively affect sleep, mood, concentration, daily activities, and overall quality of life.
Participants enrolled in this study will receive acupuncture treatment over a defined treatment period. The study will assess changes in hot flash frequency, severity, and quality of life using patient questionnaires and symptom diaries. Participants will complete a daily hot flash diary during selected 7-day assessment periods and quality-of-life questionnaires during study visits.
The primary goal of this study is to determine whether acupuncture may improve hot flash symptoms and related quality of life in men undergoing treatment for prostate cancer.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Hot flashes are a common and bothersome side effect experienced by men receiving androgen deprivation therapy (ADT) for prostate cancer. Symptoms may include sudden warmth, sweating, flushing, sleep disturbance, fatigue, mood changes, and reduced quality of life. Although medications such as antidepressants may help some patients, these treatments may also cause side effects and are not effective for all individuals. Acupuncture has been studied as a non-drug approach for management of hot flashes, but additional prospective studies are needed in men with prostate cancer receiving ADT.
This study is a prospective clinical study evaluating acupuncture for the management of ADT-related hot flashes in men with prostate cancer. Participants will undergo acupuncture treatment during the active treatment phase according to the study treatment schedule.
The study will evaluate changes in:
Hot flash frequency Hot flash severity Hot flash-related quality of life Interference of hot flashes with daily activities, sleep, mood, and social functioning
Patient-reported outcomes will be collected using standardized symptom assessments, including:
A Hot Flash Daily Diary The Hot Flash Related Daily Interference Scale (HFRDIS)
Participants will complete a daily hot flash diary during predefined 7-day assessment windows at baseline, during treatment, at the end of treatment, and during follow-up. The diary records the number and severity of hot flashes experienced over a 24-hour period. Participants will also complete questionnaires evaluating how hot flashes affect daily activities and quality of life.
The study includes follow-up assessments after completion of acupuncture treatment to evaluate the durability of symptom improvement over time.
The primary objective of the study is to assess whether acupuncture reduces hot flash burden in men receiving ADT for prostate cancer. Secondary objectives include evaluation of quality-of-life outcomes, symptom trajectory over time, treatment feasibility, and patient adherence to acupuncture-based symptom management.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Zin Myint, MD
- Telefonnummer: 850-323-3964
- E-post: zwmy222@uky.edu
Studera Kontakt Backup
- Namn: Maria Hoover, BS
- Telefonnummer: 859-323-3065
- E-post: Maria.Hoover@uky.edu
Studieorter
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- Rekrytering
- University of Kentucky
-
Kontakt:
- Zin Myint, MD
- E-post: zin.myint@uky.edu
-
Huvudutredare:
- Zin Myint, MD
-
Underutredare:
- Courtney Lantz, Dipl. Ac., L. Ac
-
Kontakt:
- Maria Hoover, BS
- Telefonnummer: 859-323-3065
- E-post: Maria.Hoover@uky.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Patients with history of prostate cancer with currently receiving hormone therapy or had received hormone therapy in the past two years
- Hormone therapies may include androgen deprivation therapy ( ADT; e.g., leuprolide, degarelix, or relugolix) or androgen signaling inhibitors (e.g., enzalutamide, apalutamide, or darolutamide) or adrenal steroid synthesis inhibitor (e.g., abiraterone acetate).
- Patients may also receive additional treatments such as chemotherapy, radioligand therapy or target therapy in combination with hormone therapy.
- Reports hot flashes at least twice per day. Patients may already be taking medications for hot flashes. There is no limit on the number of hot flash medications they can be using.
- ECOG performance status =3 (see Appendix A).
- Patients may participate in other therapeutic clinical trials for the treatment of prostate cancer. They will remain eligible as long as they meet the eligible criteria.
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
- Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.
- Patients with a prior or concurrent malignancy are eligible for this trial.
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- Patients can't travel for acupuncture
- Patients with high bleeding tendency as determined by PI
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Real Acupuncture
Participants receive acupuncture administered by a licensed and NCCAOM board certified acupuncturist at predefined acupuncture points twice weekly for 6 weeks followed by a 4 week washout period before participants crossover to the sham acupuncture arm.
|
The Real Acupuncture is administered at bilateral Large Intestine 4, Kidney 7, Kidney 3, and Gall Bladder 39 points using sterile single-use filiform needles.
Needles are inserted approximately 20-25 mm with manipulation to achieve de qi sensation and retained for 30 minutes.
Treatments are administered twice weekly for 6 weeks.
|
|
Aktiv komparator: Sham Acupuncture
Participants receive acupuncture administered by a licensed and NCCAOM board certified acupuncturist at non-acupuncture points twice weekly for 6 weeks followed by a 4 week washout period before participants crossover to the real acupuncture arm.
|
The Sham Acupuncture administered at non-acupuncture points bilaterally using sterile single-use filiform needles.
Needles are inserted approximately 4-5 mm without manipulation.
Needles are retained for 30 minutes.
Treatments are administered twice weekly for 6 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Hot Flash Score
Tidsram: Baseline and week 6
|
Weekly hot flash score will be calculated from a 7-day hot flash diary.
Daily hot flash score is calculated as the number of hot flashes per day multiplied by the maximum severity score for that day.
Weekly hot flash score is calculated as the sum of daily hot flash scores over 7 days.
The primary outcome is the change in weekly hot flash score from baseline to Week 6.
|
Baseline and week 6
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Hot Flash Related Daily Interference Scale (HFRDIS) Score
Tidsram: Baseline, Week 6, Week 16
|
Change in Hot Flash Related Daily Interference Scale (HFRDIS) total score from baseline.
The HFRDIS is a validated 10-item patient-reported questionnaire assessing the impact of hot flashes on daily functioning and quality of life.
Each item is scored from 0 to 10, with higher scores indicating greater interference from hot flashes.
|
Baseline, Week 6, Week 16
|
|
Proportion of Participants Achieving ≥50% Reduction in Weekly Hot Flash Score
Tidsram: Week 6 and Week 16
|
Proportion of participants achieving at least a 50% reduction in weekly hot flash score compared with baseline, based on 7-day hot flash diary assessments.
|
Week 6 and Week 16
|
|
Change in Mean Daily Hot Flash Frequency
Tidsram: Baseline, Week 6, Week 16
|
Change in the mean number of daily hot flashes recorded in the 7-day hot flash diary compared with baseline.
|
Baseline, Week 6, Week 16
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Prostatiska neoplasmer
- Värmevallningar
Andra studie-ID-nummer
- 111460
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .